Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
68 hedge funds and large institutions have $913M invested in Ambrx Biopharma Inc in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 9 closing their positions.
278% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 9
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
61% more capital invested
Capital invested by funds: $568M → $913M (+$345M)
55% more funds holding
Funds holding: 44 → 68 (+24)
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
26% more call options, than puts
Call options by funds: $4.72M | Put options by funds: $3.74M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$42.2M |
| 2 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$35.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.5M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$22.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$40.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$23.5M |
| 3 |
Holocene Advisors
New York
|
-$5.6M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$4.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.26M |
AMAM Hedge Fund Activity: Q4 2023 in Review
68 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q4 2023, worth a combined $913M — up 61% from $568M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AMAM positions and 9 closed out — a net gain of 25 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $42.2M. The largest seller was Commodore Capital, exiting entirely with an estimated $40.5M sold.
- 68 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q4 2023, up from 44 in Q3 2023.
- Funds reported $913M of Ambrx Biopharma Inc stock for Q4 2023, up 61% quarter-over-quarter.
- 34 funds opened new Ambrx Biopharma Inc positions in Q4 2023 and 9 closed out, a net change of +25 holders.
- The largest Ambrx Biopharma Inc buyer in Q4 2023 was Deep Track Capital, an estimated $42.2M added.
- The largest Ambrx Biopharma Inc seller in Q4 2023 was Commodore Capital, an estimated $40.5M sold.
Based on aggregated 13F filings for Q4 2023.